NCT05606471View on ClinicalTrials.gov

Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets

PHASE4UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

July 28, 2023

Study Completion Date

July 28, 2023

Conditions
Type 2 Diabetes Mellitus in Obese
Interventions
DRUG

Semaglutide Pen Injector [Ozempic]

Glucagon-like peptide 1 (GLP-1) receptor agonist

DIETARY_SUPPLEMENT

Very-low Calorie Diet

Total meal replacement with a limit of 800 kilocalories per day

Trial Locations (1)

DE22 3DT

RECRUITING

University of Nottingham, Royal Derby Hospital Centre, Derby

Sponsors

Collaborators (1)

Medical Research Council
All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

lead

University of Nottingham

OTHER